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Atrial fibrillation (AF) is a common clinical condition that 
is associated with increased morbidity and mortality that 
mainly relates to an embolic stroke. Dominant risk factors 
for AF are advanced age and hypertension in the absence 
of mitral valve disease.1 In turn, hypertension and ageing are 
determinants of the congestive heart failure, hypertension, 
age, diabetes mellitus, prior stroke or transient ischaemic 
attack or thromboembolism (CHADS2) criteria for assessing 
the indication for anticoagulation. In addition, they are 
important risk factors for chronic kidney disease (CKD). 
In itself, CKD is an independent risk factor for AF and a 
higher risk of stroke.2 It is highly likely that a practitioner 
will encounter older patients with AF and concomitant 
hypertension and CKD that require anticoagulation therapy. 
Thus, it is essential for the practitioner to understand the 
risks and benefits of anticoagulation in older patients with 
AF, hypertension and CKD. 
CKD is defined by glomerular filtration rate (GFR), usually 
estimated from the serum creatinine by a variety of equa-
tions, generally the Modification of Diet in Renal Disease in 
South Africa. CKD is defined by five stages. Stage 1: 90 ml/
minute, stage 2: 60-90 ml/minute, stage 3: 30-60 ml/min-
ute, stage 4: 15-30 ml/minute and stage 5 (or end-stage) 
< 15 ml/minute. It is also important to recognise that the 
calculation of estimated GFR (eGFR) is an epidemiological 
tool that has useful clinical utility. However, there may be an 
important underestimation or overestimation of true GFR in 
the individual patient. This can be particularly pertinent in 
older people, who are frail with reduced muscle bulk renal 
function that may be underestimated. Kidney function is an 
important determinant of the pharmacokinetics of a variety 
of drugs. This is particularly important in drugs with a nar-
row therapeutic and toxic range, such as anticoagulants.
Historically, warfarin has been the mainstay of anticoagulation 
in patients with AF. However, a large observational study 
has suggested that compared to placebo, warfarin is 
associated with increased risk of stroke, both ischaemic and 
haemorrhagic, in patients with advanced CKD, compared 
to no therapy, even when international normalised ratio 
(INR) levels are within the therapeutic range.3 Warfarin 
is considered to be contraindicated in patients with CKD 
stages 4 and 5. It also blocks Vitamin K2, which may be 
important in the prevention of vascular calcification, highly 
prevalent in the CKD population.4
Recent publications of major studies that attested to 
the safety and efficacy of the newer anticoagulants, 
dabigatran, rivaroxaban, and apixaban, heralded a new 
era in anticoagulation for patients with AF. In particular, 
dabigatran 150 mg was shown to be superior to warfarin, 
and was registered for use by the US Food and Drug 
Administration.5-7 However, in 2012, there was concern 
about excess bleeding in older patients who were switched 
from warfarin to dabigatran by the Haematology Society of 
Australia and New Zealand.8 In two months, approximately 
7 000 patients started on dabigatran treatment. Seventy-
eight cases of haemorrhage were reported, of which 12 
were major. Two thirds occurred in patients over 80 years 
old, 58% with renal impairment and 50% with reduced 
mass. A recent report from the US has suggested that the 
bleeding risk in this population may even be higher than in 
that taking warfarin.9  Of note, in the Randomized Evaluation 
of Long-term Anticoagulant Therapy (RELY) study, patients 
were younger, heavier and with better kidney function.5 The 
recommendation of a single dose, without being cognisant 
of renal function, seems to have been an error. A better 
understanding of the pharmacokinetics of dabigatran is 
helpful in understanding the dangers of anticoagulation. 
Eighty percent of dabigatran is excreted unchanged in the 
urine, and the pharmacokinetics is highly influenced by 
renal function, with marked prolongation of the half-life.10 
Currently, it is now considered to be contraindicated in CKD 
stages 4 and 5. There should be a dose reduction in CKD 
stage 3. On the other hand, rivoraxaban has a different 
pharmacokinetic profile. 9 Only one third is excreted 
unchanged in the urine and two thirds is metabolised. 
Concentrations and half-life are less influenced by renal 
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function. In the Rivoraxaban versus Warfarin in Nonvalvular 
Atrial Fibrillation (ROCKET) study, rivaroxaban was used 
in a dose of 20 mg daily with eGFR ≥ 50 ml/minute, but 
reduced to 15 mg if the eGFR was 30-49 ml/minute. This 
provided invaluable information about its safety when it is 
used in patients with reduced renal function. There was no 
difference in the primary efficacy outcome in patients with 
reduced, compared to normal, renal function, but there 
was significant reduction in fatal haemorrhage.11 Currently, 
it is recommended that the dose of rivaroxaban in atrial 
fibrillation should be reduced in CKD stage 3 from 20 mg 
to 15 mg daily. It has not been tested in patients with CKD 
stage 4 and is contraindicated in CKD stage 5. 
In the Apixaban versus Warfarin in Patients with Atrial 
Fibrillation (ARISTOTLE) trial, apixaban or matching 
placebo was administered twice daily. Apixaban was given 
in 5-mg doses, but interestingly, 2.5-mg doses were used 
in a subset of patients with two or more of the following 
criteria: age of at least 80 years, body weight of no more 
than 60 kg and serum creatinine level ≥ 133 μmol/l. Clearly 
the investigators had learnt from experience, and in this 
subset, the primary efficacy and safety outcomes mirrored 
the main study results.7
These issues raise pertinent questions about the responsible 
prescribing of anticoagulants. There are no completely safe 
anticoagulants. Increased risk of haemorrhage needs to be 
balanced by the benefits of the prevention of thrombosis 
and embolic stroke. In the case of atrial fibrillation, every 
patient needs to be assessed for anticoagulation using 
either the CHADS2 or CHA2DS2VASc criteria to determine 
the indication for anticoagulation. A score ≥ 1 indicates 
a need for anticoagulation. This needs to be balanced 
against the risk of haemorrhage. The development of the 
hypertension, abnormal renal or liver function, stroke history, 
bleeding history or predisposition, labile INR, elderly (age 
> 65) and drugs and alcohol use concomitantly (HAS-BLED) 
criteria (see Table I) is a useful tool to assess the risk of 
haemorrhage.12,13 Age, uncontrolled hypertension and CKD 
are important components of these criteria.
Although the new anticoagulants represent a significant 
advance over warfarin, chiefly because of the stability of 
anticoagulation and significantly fewer drug interactions, 
this does not mean that “one dose fits all” and that there 
is no need for monitoring. There is a significant need to 
develop tools to assess the degree of anticoagulation, 
particularly in the high-risk population described above. 
In the author’s opinion, this will create a significant safety 
net to avoid haemorrhagic complications that are caused 
by excessive anticoagulation and increase physician 
confidence in the newer drugs. 
Another critically important need is to develop reliable 
antidotes to reverse life-threatening bleeding. At least 
with warfarin, the prolonged INR can be readily reversed 
by Vitamin K and fresh frozen plasma, but reversal of the 
effects of the newer anticoagulants needs to be established.
In conclusion, the treatment of elderly patients with AF, with 
CKD and hypertension presents many challenges. Warfarin 
and dabigatran are contraindicated in CKD stages 4 and 
5. Rivaroxaban and apixaban probably have better safety 
profiles in CKD, but further studies are required in this 
population which is generally excluded from clinical trials, 
and yet constitutes a significant number of patients with a 
clinical indication for anticoagulants.
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Table I: HAS-BLED criteria for assessing haemorrhage (the higher the 
score, the greater the risk)
 H Hypertension (> 160) 1 
A Abnormal renal or liver function 1 or 2 
S Stroke 1 
B Bleeding 1 
L Labile INR (< 60% TR) 1 
E Elderly (> 65) 1 
D Drugs and alcohol concomitantly 1 or 2 
INR: international normalised ratio, TR: therapeutic range
D
ow
nl
oa
de
d 
by
 [
U
ni
ve
rs
ity
 o
f 
C
ap
e 
T
ow
n 
L
ib
ra
ri
es
] 
at
 0
1:
34
 2
1 
A
pr
il 
20
16
 
